Retatrutide clinical trials

Status: Retatrutide is investigational and not approved by the FDA or any other regulator. Eli Lilly has said it plans to submit a Biologics License Application to the FDA in the first quarter of 2027; no submission, priority review or decision date has been announced.

Head-to-head evidence: One randomized comparison has reported: TRANSCEND-T2D-2, an open-label trial in type 2 diabetes against semaglutide 2 mg (Ozempic), so far only as a topline press release. The comparison with tirzepatide, TRIUMPH-5, is registered and has not reported.

20 trials tracked: 10 with reported results, 10 registered without results yet. Verified against each source on November 8, 2026.

Retatrutide is a once-weekly injected agonist of three receptors: GIP, GLP-1 and glucagon. Semaglutide acts on GLP-1 alone and tirzepatide on GIP and GLP-1; the glucagon receptor is the addition, intended to raise energy expenditure. Its half-life is approximately 6 days (phase 1b).

Research and educational reference only. Trial arms are the regimens studied under medical supervision, not an amount for anyone to take. Nothing here is medical advice.

All trials at a glance

Retatrutide trials: phase, population, size, comparator, status and whether results are reported
Trial	Phase	Population	Size	Comparator	Status	Results
TRIUMPH-1 NCT05929066	3	Adults with obesity or overweight without type 2 diabetes (with knee osteoarthritis and sleep apnea substudies)	2,339	Placebo	Completed	Published, Topline (press release)
TRIUMPH-2 NCT05929079	3	Adults with type 2 diabetes and obesity or overweight	1,152	Placebo	Completed	Published
TRIUMPH-3 NCT05882045	3	Adults with severe obesity and established cardiovascular disease	1,949	Placebo	Completed	Topline (press release)
TRIUMPH-4 NCT05931367	3	Adults with obesity or overweight and knee osteoarthritis (84% with BMI ≥35)	445	Placebo	Completed	Topline (press release)
TRANSCEND-T2D-1 NCT06354660	3	Adults with type 2 diabetes managed with diet and exercise	537	Placebo	Completed	Published
TRANSCEND-T2D-2 (vs semaglutide)NCT06260722	3	Adults with type 2 diabetes on metformin, with or without an SGLT2 inhibitor	1,298	Semaglutide 2 mg (Ozempic), open-label	Active, not recruiting	Topline (press release)
TRIUMPH-1-OSA and TRIUMPH-2-OSA	3	Adults with obesity and obstructive sleep apnea (substudies of TRIUMPH-1 and TRIUMPH-2)	691	Placebo	Completed	Published
Phase 2 obesity trial NCT04881760	2	Adults with obesity, or overweight with a weight-related condition, without diabetes	338	Placebo	Completed	Published
Phase 2 type 2 diabetes trial NCT04867785	2	Adults with type 2 diabetes (HbA1c 7.0–10.5%, BMI 25–50) on diet and exercise or metformin	281	Placebo and dulaglutide 1.5 mg	Completed	Published
Phase 2 liver-fat substudy (MASLD)	2	Participants of the phase 2 obesity trial with MASLD and ≥10% liver fat	98	Placebo	Completed	Published
Phase 1b multiple-dose trial NCT04143802	1b	Adults with type 2 diabetes	72	Placebo and dulaglutide 1.5 mg	Completed	None yet
TRIUMPH-5 (vs tirzepatide)NCT06662383	3	Adults with obesity	800 planned	Tirzepatide, double-blind	Active, not recruiting	None yet
TRIUMPH-Outcomes NCT06383390	3	Adults with BMI ≥27 and atherosclerotic cardiovascular disease and/or chronic kidney disease	10,000 planned	Placebo	Active, not recruiting	None yet
TRIUMPH-6 NCT06859268	3b	Adults with obesity: maintenance of weight reduction	643 planned	Placebo (switch after week 80)	Active, not recruiting	None yet
TRIUMPH-7 NCT07035093	3	Adults with obesity or overweight and chronic low back pain	586 planned	Placebo	Active, not recruiting	None yet
TRIUMPH-8 NCT07232719	3b	Adults with obesity or overweight without type 2 diabetes	250 planned	Placebo	Active, not recruiting	None yet
TRIUMPH-9 NCT07357415	3b	Adults with obesity or overweight without type 2 diabetes: escalation schemes	600 planned	Retatrutide escalation schemes compared with each other	Active, not recruiting	None yet
TRANSCEND-T2D-3 NCT06297603	3	Adults with type 2 diabetes and moderate or severe kidney impairment on basal insulin	320 planned	Placebo	Active, not recruiting	None yet
TRANSCEND-CKD NCT05936151	2	Adults with chronic kidney disease	146	Placebo	Completed	None yet
MASLD outcomes master protocol NCT07165028	3	Adults with MASLD at increased risk of major adverse liver outcomes	4,500 planned	Placebo within each sub-protocol (retatrutide and tirzepatide sub-protocols are separate, not head-to-head)	Recruiting	None yet

The weight outcomes are charted arm by arm on Retatrutide weight loss results.

Trials with reported results

Each trial is its own comparison against its own control group. Figures from different trials differ in population, duration and estimand and are not compared with each other here.

TRIUMPH-1

NCT05929066 on ClinicalTrials.gov

Phase: Phase 3
Status: Completed
Population: Adults with obesity or overweight without type 2 diabetes (with knee osteoarthritis and sleep apnea substudies)
Randomized: 2,339
Duration: 80 weeks (24-week extension in participants with BMI ≥35)
Comparator: Placebo
Primary endpoint: Percent change in body weight at week 80

Arms as registered or published: Retatrutide 4 mg; Retatrutide 9 mg; Retatrutide 12 mg; Placebo (1:1:1:1)

Reported results

TRIUMPH-1: Mean % change in body weight, Week 80Treatment-regimen estimand (the paper’s primary analysis)

TRIUMPH-1: Mean % change in body weight at Week 80, by arm
Arm	Reported
Retatrutide 4 mg	−17.6%
Retatrutide 9 mg	−23.7%
Retatrutide 12 mg	−25.0%
Placebo(comparator)	−3.9%

Peer-reviewed publication: Jastreboff AM, et al. N Engl J Med 2026;395:1781-1793 (TRIUMPH-1)

Adverse events reported

TRIUMPH-1: adverse events by arm
Event	4 mg	9 mg	12 mg	Placebo
Nausea	28.6%	38.4%	42.4%	14.8%
Diarrhea	25.2%	34.1%	32.0%	13.5%
Constipation	23.8%	25.9%	26.1%	10.9%
Vomiting	10.6%	22.8%	25.3%	4.8%
Dysesthesia (altered skin sensation)	5.1%	12.3%	12.5%	0.9%
Stopped treatment because of adverse events	4.1%	6.9%	11.3%	4.9%

Percent of participants, as reported in Eli Lilly press release, 2026-05-21 (TRIUMPH-1 topline).

Adverse event rates are from Lilly’s 2026-05-21 topline release; Lilly’s medical-information page gives slightly different discontinuation figures from a later data cut.
In the 532 participants with BMI ≥35 who continued to week 104, the 12 mg arm reported −29.9% (treatment-regimen estimand) in the topline release.

Sources

Peer-reviewed publication: Jastreboff AM, et al. N Engl J Med 2026;395:1781-1793 (TRIUMPH-1) · PMID 42814954
Sponsor topline release (not peer-reviewed): Eli Lilly press release, 2026-05-21 (TRIUMPH-1 topline)
Trial registration: NCT05929066, ClinicalTrials.gov (checked 2026-11-08)

TRIUMPH-2

NCT05929079 on ClinicalTrials.gov

Phase: Phase 3
Status: Completed
Population: Adults with type 2 diabetes and obesity or overweight
Randomized: 1,152
Duration: 80 weeks
Comparator: Placebo
Primary endpoint: Percent change in body weight at week 80

Arms as registered or published: Retatrutide 4 mg (n=292); Retatrutide 9 mg (n=284); Retatrutide 12 mg (n=287); Placebo (n=289)

Reported results

TRIUMPH-2: Mean % change in body weight, Week 80Treatment-regimen estimand

TRIUMPH-2: Mean % change in body weight at Week 80, by arm
Arm	Reported	Analysed
Retatrutide 4 mg	−11.9%	n=292
Retatrutide 9 mg	−16.8%	n=284
Retatrutide 12 mg	−18.8%	n=287
Placebo(comparator)	−5.1%	n=289

Peer-reviewed publication: Bellido V, et al. Lancet 2026;408:1455-1472 (TRIUMPH-2)

Adverse events reported

TRIUMPH-2: adverse events by arm
Event	4 mg	9 mg	12 mg	Placebo
Diarrhea	27%	34%	34%	13%
Nausea	14%	21%	28%	8%
Dysesthesia	4%	6%	7%	1%
Hypotension	1%	5%	6%	<1%
Stopped treatment because of adverse events or death	4%	12%	8%	5%

Percent of participants, as reported in Bellido V, et al. Lancet 2026;408:1455-1472 (TRIUMPH-2).

Lilly’s 2026-07-23 topline release reported the efficacy estimand instead (−20.8% at 12 mg vs −4.0% placebo) and A1C changes the abstract does not give.

Sources

Peer-reviewed publication: Bellido V, et al. Lancet 2026;408:1455-1472 (TRIUMPH-2) · PMID 42810372
Sponsor topline release (not peer-reviewed): Eli Lilly press release, 2026-07-23 (TRIUMPH-2 and TRIUMPH-3 topline)
Trial registration: NCT05929079, ClinicalTrials.gov (checked 2026-11-08)

TRIUMPH-3

NCT05882045 on ClinicalTrials.gov

Phase: Phase 3
Status: Completed
Population: Adults with severe obesity and established cardiovascular disease
Randomized: 1,949
Duration: 80 weeks
Comparator: Placebo
Primary endpoint: Percent change in body weight at week 80

Arms as registered or published: Retatrutide 9 mg; Retatrutide 12 mg; Placebo (1:1:2)

Reported results

TRIUMPH-3: Mean % change in body weight, Week 80Efficacy estimand, from Lilly’s topline release (no peer-reviewed paper yet)

TRIUMPH-3: Mean % change in body weight at Week 80, by arm
Arm	Reported
Retatrutide 9 mg	−21.6%
Retatrutide 12 mg	−22.6%
Placebo(comparator)	−3.2%

Sponsor topline release (not peer-reviewed): Eli Lilly press release, 2026-07-23 (TRIUMPH-2 and TRIUMPH-3 topline)

Adverse events reported

TRIUMPH-3: adverse events by arm
Event	9 mg	12 mg	Placebo
Stopped treatment because of adverse events	9.8%	13.5%	4.8%

Percent of participants, as reported in Eli Lilly press release, 2026-07-23 (TRIUMPH-2 and TRIUMPH-3 topline).

Lilly also reported in-trial cardiovascular events pooled across retatrutide arms (MACE-5 hazard ratio 0.82, 95% CI 0.55 to 1.22). This is a weight trial, events were fewer than expected and the interval includes no effect: it is not cardiovascular outcome evidence. TRIUMPH-Outcomes is the trial designed for that.

Sources

Sponsor topline release (not peer-reviewed): Eli Lilly press release, 2026-07-23 (TRIUMPH-2 and TRIUMPH-3 topline)
Trial registration: NCT05882045, ClinicalTrials.gov (checked 2026-11-08)

TRIUMPH-4

NCT05931367 on ClinicalTrials.gov

Phase: Phase 3
Status: Completed
Population: Adults with obesity or overweight and knee osteoarthritis (84% with BMI ≥35)
Randomized: 445
Duration: 68 weeks
Comparator: Placebo
Primary endpoint: WOMAC pain and percent change in body weight at week 68

Arms as registered or published: Retatrutide 9 mg; Retatrutide 12 mg; Placebo (1:1:1)

Reported results

TRIUMPH-4: Mean % change in body weight, Week 68Treatment-regimen estimand, from Lilly’s topline release (no peer-reviewed paper yet)

TRIUMPH-4: Mean % change in body weight at Week 68, by arm
Arm	Reported
Retatrutide 9 mg	−20.0%
Retatrutide 12 mg	−23.7%
Placebo(comparator)	−4.6%

Sponsor topline release (not peer-reviewed): Eli Lilly press release, 2025-12-11 (TRIUMPH-4 topline)

Adverse events reported

TRIUMPH-4: adverse events by arm
Event	9 mg	12 mg	Placebo
Nausea	38.1%	43.2%	10.7%
Diarrhea	34.7%	33.1%	13.4%
Constipation	21.8%	25.0%	8.7%
Vomiting	20.4%	20.9%	0.0%
Dysesthesia	8.8%	20.9%	0.7%
Stopped treatment because of adverse events	12.2%	18.2%	4.0%

Percent of participants, as reported in Eli Lilly press release, 2025-12-11 (TRIUMPH-4 topline).

Lilly’s release gives NCT05869903 for this trial; that number belongs to a different Lilly trial (ATTAIN-1, orforglipron). The ClinicalTrials.gov record for TRIUMPH-4 is NCT05931367.
Mean baseline weight was 112.7 kg (BMI 40.4), heavier than in TRIUMPH-1.

Sources

Sponsor topline release (not peer-reviewed): Eli Lilly press release, 2025-12-11 (TRIUMPH-4 topline)
Trial registration: NCT05931367, ClinicalTrials.gov (checked 2026-11-08)

TRANSCEND-T2D-1

NCT06354660 on ClinicalTrials.gov

Phase: Phase 3
Status: Completed
Population: Adults with type 2 diabetes managed with diet and exercise
Randomized: 537
Duration: 40 weeks
Comparator: Placebo
Primary endpoint: HbA1c change at week 40

Arms as registered or published: Retatrutide 4 mg (n=134); Retatrutide 9 mg (n=133); Retatrutide 12 mg (n=136); Placebo (n=134)

Reported results

TRANSCEND-T2D-1: Mean % change in body weight, Week 40Treatment-regimen estimand

TRANSCEND-T2D-1: Mean % change in body weight at Week 40, by arm
Arm	Reported	Analysed
Retatrutide 4 mg	−11.5%	n=134
Retatrutide 9 mg	−13.9%	n=133
Retatrutide 12 mg	−15.3%	n=136
Placebo(comparator)	−2.6%	n=134

Peer-reviewed publication: Bajaj HS, et al. Lancet 2026;407:2402-2413 (TRANSCEND-T2D-1)

Stopping treatment because of adverse events was reported as 2–5% with retatrutide and 0% with placebo; no severe hypoglycemia.

Sources

Peer-reviewed publication: Bajaj HS, et al. Lancet 2026;407:2402-2413 (TRANSCEND-T2D-1) · PMID 42250575
Trial registration: NCT06354660, ClinicalTrials.gov (checked 2026-11-08)

TRANSCEND-T2D-2 (vs semaglutide)

NCT06260722 on ClinicalTrials.gov

Phase: Phase 3
Status: Active, not recruiting
Population: Adults with type 2 diabetes on metformin, with or without an SGLT2 inhibitor
Randomized: 1,298
Duration: 80 weeks
Comparator: Semaglutide 2 mg (Ozempic), open-label
Primary endpoint: HbA1c change at week 80 (noninferiority of 12 mg vs semaglutide 2 mg)

Arms as registered or published: Retatrutide 9 mg; Retatrutide 12 mg; Semaglutide (Ozempic) 2 mg (2:2:1)

Reported results

TRANSCEND-T2D-2 (vs semaglutide): Mean % change in body weight, Week 80Efficacy estimand only, from Lilly’s topline release (no peer-reviewed paper yet)

TRANSCEND-T2D-2 (vs semaglutide): Mean % change in body weight at Week 80, by arm
Arm	Reported
Retatrutide 9 mg	−19.5%
Retatrutide 12 mg	−20.9%
Semaglutide 2 mg(comparator)	−9.4%

Sponsor topline release (not peer-reviewed): Eli Lilly press release, 2026-10-28 (TRANSCEND-T2D-2 topline)

Adverse events reported

TRANSCEND-T2D-2 (vs semaglutide): adverse events by arm
Event	9 mg	12 mg	Semaglutide 2 mg
Stopped treatment because of adverse events	4.8%	7.9%	2.7%

Percent of participants, as reported in Eli Lilly press release, 2026-10-28 (TRANSCEND-T2D-2 topline).

The first randomized trial of retatrutide against another incretin medicine. It is open-label, in type 2 diabetes, and so far reported only as a press release using the efficacy estimand.
The registry still lists an estimated enrollment of 1,250; Lilly reports 1,298 randomized.

Sources

Sponsor topline release (not peer-reviewed): Eli Lilly press release, 2026-10-28 (TRANSCEND-T2D-2 topline)
Trial registration: NCT06260722, ClinicalTrials.gov (checked 2026-11-08)

TRIUMPH-1-OSA and TRIUMPH-2-OSA

Phase: Phase 3
Status: Completed
Population: Adults with obesity and obstructive sleep apnea (substudies of TRIUMPH-1 and TRIUMPH-2)
Randomized: 691
Duration: 80 weeks
Comparator: Placebo
Primary endpoint: Change in apnea-hypopnea index (AHI) at week 80

Reported results

TRIUMPH-1-OSA and TRIUMPH-2-OSA: AHI change (TRIUMPH-1-OSA, no diabetes, n=243), Week 80Hybrid estimand

TRIUMPH-1-OSA and TRIUMPH-2-OSA: AHI change (TRIUMPH-1-OSA, no diabetes, n=243) at Week 80, by arm
Arm	Reported
Retatrutide 4 mg	−22.9 events per hour
Retatrutide 9 mg	−34.3 events per hour
Retatrutide 12 mg	−31.7 events per hour
Placebo(comparator)	−9.9 events per hour

Peer-reviewed publication: Grunstein RR, et al. N Engl J Med 2026 (online Oct 21; TRIUMPH-1-OSA and TRIUMPH-2-OSA)

Sources

Peer-reviewed publication: Grunstein RR, et al. N Engl J Med 2026 (online Oct 21; TRIUMPH-1-OSA and TRIUMPH-2-OSA) · PMID 42904878
Trial registration: NCT05929066, ClinicalTrials.gov (checked 2026-11-08)
Trial registration: NCT05929079, ClinicalTrials.gov (checked 2026-11-08)

Phase 2 obesity trial

NCT04881760 on ClinicalTrials.gov

Phase: Phase 2
Status: Completed
Population: Adults with obesity, or overweight with a weight-related condition, without diabetes
Enrolled: 338
Duration: 48 weeks
Comparator: Placebo
Primary endpoint: Percent change in body weight at week 24

Arms as registered or published: Retatrutide 1 mg; 4 mg (two starting schemes, combined); 8 mg (two starting schemes, combined); 12 mg; Placebo

Reported results

Phase 2 obesity trial: Mean % change in body weight, Week 48Efficacy estimand (least-squares mean)

Phase 2 obesity trial: Mean % change in body weight at Week 48, by arm
Arm	Reported
Retatrutide 1 mg	−8.7%
Retatrutide 4 mg	−17.1%
Retatrutide 8 mg	−22.8%
Retatrutide 12 mg	−24.2%
Placebo(comparator)	−2.1%

Peer-reviewed publication: Jastreboff AM, et al. N Engl J Med 2023;389:514-526

Adverse events reported

Phase 2 obesity trial: adverse events by arm
Event	Placebo	1 mg	4 mg (start 2)	4 mg (start 4)	8 mg (start 2)	8 mg (start 4)	12 mg
Nausea	11%	14%	18%	36%	17%	60%	45%
Diarrhea	11%	9%	12%	12%	20%	20%	15%
Vomiting	1%	3%	12%	12%	6%	26%	19%
Constipation	3%	7%	15%	6%	11%	11%	16%
Stopped treatment because of adverse events	0%	7%	6%	9%	14%	6%	16%

Percent of participants, as reported in Jastreboff AM, et al. N Engl J Med 2023;389:514-526.

Serious adverse events occurred in 4% of both the retatrutide and placebo groups. Heart rate rose with dose, peaked at week 24 and declined afterwards.
Skin sensitivity (cutaneous hyperesthesia) was reported in 7% on retatrutide and 1% on placebo.
Starting at 2 mg rather than 4 mg partly reduced gastrointestinal events, which is why later trials escalate gradually.

Sources

Peer-reviewed publication: Jastreboff AM, et al. N Engl J Med 2023;389:514-526 · PMID 37366315
Trial registration: NCT04881760, ClinicalTrials.gov (checked 2026-11-08)

Phase 2 type 2 diabetes trial

NCT04867785 on ClinicalTrials.gov

Phase: Phase 2
Status: Completed
Population: Adults with type 2 diabetes (HbA1c 7.0–10.5%, BMI 25–50) on diet and exercise or metformin
Randomized: 281
Duration: 36 weeks
Comparator: Placebo and dulaglutide 1.5 mg
Primary endpoint: HbA1c change at week 24

Reported results

Phase 2 type 2 diabetes trial: Mean % change in body weight, Week 36Least-squares mean, as reported in the abstract

Phase 2 type 2 diabetes trial: Mean % change in body weight at Week 36, by arm
Arm	Reported
Retatrutide 0.5 mg	−3.19%
Retatrutide 4 mg (escalated)	−7.92%
Retatrutide 4 mg	−10.37%
Retatrutide 8 mg (slow)	−16.81%
Retatrutide 8 mg (fast)	−16.34%
Retatrutide 12 mg	−16.94%
Placebo(comparator)	−3.0%
Dulaglutide 1.5 mg(comparator)	−2.02%

Peer-reviewed publication: Rosenstock J, et al. Lancet 2023;402:529-544

Mild-to-moderate gastrointestinal events: 35% on retatrutide overall (13% at 0.5 mg to 50% at 8 mg fast escalation), 13% on placebo, 35% on dulaglutide. No severe hypoglycemia and no deaths.

Sources

Peer-reviewed publication: Rosenstock J, et al. Lancet 2023;402:529-544 · PMID 37385280
Trial registration: NCT04867785, ClinicalTrials.gov (checked 2026-11-08)

Phase 2 liver-fat substudy (MASLD)

Phase: Phase 2
Status: Completed
Population: Participants of the phase 2 obesity trial with MASLD and ≥10% liver fat
Randomized: 98
Duration: 48 weeks (primary outcome at 24 weeks)
Comparator: Placebo
Primary endpoint: Relative change in liver fat at week 24

Reported results

Phase 2 liver-fat substudy (MASLD): Relative change in liver fat, Week 24

Phase 2 liver-fat substudy (MASLD): Relative change in liver fat at Week 24, by arm
Arm	Reported
Retatrutide 1 mg	−42.9%
Retatrutide 4 mg	−57.0%
Retatrutide 8 mg	−81.4%
Retatrutide 12 mg	−82.4%
Placebo(comparator)	+0.3%

Peer-reviewed publication: Sanyal AJ, et al. Nat Med 2024;30:2037-2048

Sources

Peer-reviewed publication: Sanyal AJ, et al. Nat Med 2024;30:2037-2048 · PMID 38858523

Registered trials without results yet

These are registrations: what each trial plans to enroll and measure. A registration is not a result.

Phase 1b multiple-dose trial

NCT04143802 on ClinicalTrials.gov

Phase: Phase 1b
Status: Completed
Population: Adults with type 2 diabetes
Enrolled: 72
Duration: 12 weeks
Comparator: Placebo and dulaglutide 1.5 mg

Reported results

No results have been reported yet. Registration details describe what the trial plans to measure, not an outcome.

Pharmacokinetics were dose-proportional and the half-life was approximately 6 days, which is what supports once-weekly dosing.
Placebo-adjusted weight change reached −8.96 kg in the highest escalation cohort over 12 weeks.

Sources

Peer-reviewed publication: Urva S, et al. Lancet 2022;400:1869-1881 · PMID 36354040
Trial registration: NCT04143802, ClinicalTrials.gov (checked 2026-11-08)

TRIUMPH-5 (vs tirzepatide)

NCT06662383 on ClinicalTrials.gov

Phase: Phase 3
Status: Active, not recruiting
Population: Adults with obesity
Planned enrollment: 800
Comparator: Tirzepatide, double-blind
Primary endpoint: Percent change in body weight at week 80
Primary completion: November 2026 (estimated)

Reported results

No results have been reported yet. Registration details describe what the trial plans to measure, not an outcome.

The only registered randomized comparison of retatrutide with tirzepatide.

Sources

Trial registration: NCT06662383, ClinicalTrials.gov (checked 2026-11-08)

TRIUMPH-Outcomes

NCT06383390 on ClinicalTrials.gov

Phase: Phase 3
Status: Active, not recruiting
Population: Adults with BMI ≥27 and atherosclerotic cardiovascular disease and/or chronic kidney disease
Planned enrollment: 10,000
Comparator: Placebo
Primary endpoint: Time to first major adverse cardiovascular event; time to first kidney composite event
Primary completion: February 2029 (estimated)

Reported results

No results have been reported yet. Registration details describe what the trial plans to measure, not an outcome.

Sources

Trial registration: NCT06383390, ClinicalTrials.gov (checked 2026-11-08)

TRIUMPH-6

NCT06859268 on ClinicalTrials.gov

Phase: Phase 3b
Status: Active, not recruiting
Population: Adults with obesity: maintenance of weight reduction
Planned enrollment: 643
Comparator: Placebo (switch after week 80)
Primary endpoint: Percent change in body weight from week 0 to week 116
Primary completion: April 2028 (estimated)

Reported results

No results have been reported yet. Registration details describe what the trial plans to measure, not an outcome.

Sources

Trial registration: NCT06859268, ClinicalTrials.gov (checked 2026-11-08)

TRIUMPH-7

NCT07035093 on ClinicalTrials.gov

Phase: Phase 3
Status: Active, not recruiting
Population: Adults with obesity or overweight and chronic low back pain
Planned enrollment: 586
Comparator: Placebo
Primary endpoint: Pain score change and percent change in body weight, up to 72 weeks
Primary completion: September 2027 (estimated)

Reported results

No results have been reported yet. Registration details describe what the trial plans to measure, not an outcome.

Sources

Trial registration: NCT07035093, ClinicalTrials.gov (checked 2026-11-08)

TRIUMPH-8

NCT07232719 on ClinicalTrials.gov

Phase: Phase 3b
Status: Active, not recruiting
Population: Adults with obesity or overweight without type 2 diabetes
Planned enrollment: 250
Comparator: Placebo
Primary endpoint: Percent change in body weight at week 56
Primary completion: July 2027 (estimated)

Reported results

No results have been reported yet. Registration details describe what the trial plans to measure, not an outcome.

Sources

Trial registration: NCT07232719, ClinicalTrials.gov (checked 2026-11-08)

TRIUMPH-9

NCT07357415 on ClinicalTrials.gov

Phase: Phase 3b
Status: Active, not recruiting
Population: Adults with obesity or overweight without type 2 diabetes: escalation schemes
Planned enrollment: 600
Comparator: Retatrutide escalation schemes compared with each other
Primary endpoint: Percent change in body weight at week 104
Primary completion: October 2028 (estimated)

Reported results

No results have been reported yet. Registration details describe what the trial plans to measure, not an outcome.

Sources

Trial registration: NCT07357415, ClinicalTrials.gov (checked 2026-11-08)

TRANSCEND-T2D-3

NCT06297603 on ClinicalTrials.gov

Phase: Phase 3
Status: Active, not recruiting
Population: Adults with type 2 diabetes and moderate or severe kidney impairment on basal insulin
Planned enrollment: 320
Comparator: Placebo
Primary endpoint: HbA1c change at week 52
Primary completion: October 2026 (estimated)

Reported results

No results have been reported yet. Registration details describe what the trial plans to measure, not an outcome.

Sources

Trial registration: NCT06297603, ClinicalTrials.gov (checked 2026-11-08)

TRANSCEND-CKD

NCT05936151 on ClinicalTrials.gov

Phase: Phase 2
Status: Completed
Population: Adults with chronic kidney disease
Randomized: 146
Comparator: Placebo
Primary endpoint: Change in measured glomerular filtration rate at week 24
Primary completion: October 2025 (actual)

Reported results

No results have been reported yet. Registration details describe what the trial plans to measure, not an outcome.

Completed, but only the design and baseline paper has been published; no results yet.

Sources

Peer-reviewed publication: TRANSCEND-CKD design and baseline paper, Nephrol Dial Transplant 2026;41:1058-1068 · PMID 41160422
Trial registration: NCT05936151, ClinicalTrials.gov (checked 2026-11-08)

MASLD outcomes master protocol

NCT07165028 on ClinicalTrials.gov

Phase: Phase 3
Status: Recruiting
Population: Adults with MASLD at increased risk of major adverse liver outcomes
Planned enrollment: 4,500
Comparator: Placebo within each sub-protocol (retatrutide and tirzepatide sub-protocols are separate, not head-to-head)
Primary endpoint: Time to first major adverse liver outcome
Primary completion: August 2030 (estimated)

Reported results

No results have been reported yet. Registration details describe what the trial plans to measure, not an outcome.

Sources

Trial registration: NCT07165028, ClinicalTrials.gov (checked 2026-11-08)

Evidence quality

Peptide Library grades human evidence claim by claim with risk-of-bias tools and GRADE, published only from frozen assessments. Retatrutide has not been assessed under that method yet, which is not evidence either way. Until it is, read each trial for its design: randomized and placebo-controlled, its size and duration, and whether the figure comes from a peer-reviewed paper or a sponsor’s topline release.

How the evidence-quality method works · Retatrutide publication and trial statistics

What the trials do not answer yet

Cardiovascular and kidney outcomes: TRIUMPH-Outcomes (about 10,000 participants) is not expected to finish before 2029.
Long-term safety beyond 80–104 weeks, and rare adverse events that only a larger exposed population can show.
A blinded comparison with tirzepatide (TRIUMPH-5) and a peer-reviewed report of the semaglutide comparison.
What happens to weight after treatment stops, which TRIUMPH-6 is designed to test.
Dysesthesia (altered skin sensation) and heart-rate increases, both reported more often than with placebo and not yet fully characterized.

All trials at a glance

Trials with reported results

TRIUMPH-1

Reported results

Adverse events reported

Sources

TRIUMPH-2

Reported results

Adverse events reported

Sources

TRIUMPH-3

Reported results

Adverse events reported

Sources

TRIUMPH-4

Reported results

Adverse events reported

Sources

TRANSCEND-T2D-1

Reported results

Sources

TRANSCEND-T2D-2 (vs semaglutide)

Reported results

Adverse events reported

Sources

TRIUMPH-1-OSA and TRIUMPH-2-OSA

Reported results

Sources

Phase 2 obesity trial

Reported results

Adverse events reported

Sources

Phase 2 type 2 diabetes trial

Reported results

Sources

Phase 2 liver-fat substudy (MASLD)

Reported results

Sources

Registered trials without results yet

Phase 1b multiple-dose trial

Reported results

Sources

TRIUMPH-5 (vs tirzepatide)

Reported results

Sources

TRIUMPH-Outcomes

Reported results

Sources

TRIUMPH-6

Reported results

Sources

TRIUMPH-7

Reported results

Sources

TRIUMPH-8

Reported results

Sources

TRIUMPH-9

Reported results

Sources

TRANSCEND-T2D-3

Reported results

Sources

TRANSCEND-CKD

Reported results

Sources

MASLD outcomes master protocol

Reported results

Sources

Evidence quality

What the trials do not answer yet

Regulatory status sources